NanOlogy, LLC, a Texas-based, private clinical-stage oncology company, announced on Thursday that it has launched a drug development program aimed at transforming the treatment of diffuse intrinsic pontine glioma (DIPG), an aggressive, highly lethal paediatric brainstem tumour.
The company is developing Large Surface Area Microparticle (LSAM) Cisplatin for stereotactic intratumoral (IT) administration in this initial indication.
NanOlogy is completing Investigational New Drug (IND) enabling studies required by the US Food and Drug Administration (FDA). Upon completion of these studies, the company plans to submit an IND application for LSAM-Cisplatin to treat malignant neoplasms of the brain, including DIPG.
Subject to FDA approval to proceed, NanOlogy says that it aims to initiate a clinical trial in late 2026 to evaluate the safety and response of stereotactic IT administration of LSAM-Cisplatin in children diagnosed with DIPG.
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older